Antiplatelet drugs use situation for acute myocardial infarction patients in Vietnam

Abstract

This study aims to evaluate antiplatelet drug use and possible interactions that can occur during acute myocardial infarction treatment. We establish a cross-sectional descriptive study with 380 acute myocardial infarction inpatient cases treated with antiplatelet drugs in Vietnam in 2021. In our study, the mean age is 69.3, and most patients are over sixty-five, accounting for 67.6%. Indicated antiplatelet drugs encompass aspirin (100%), clopidogrel (86.0%), and ticagrelor (42.6%). Dual antiplatelet therapy with aspirin-clopidogrel and aspirin-ticagrelor accounts for 86.0% and 42.6%, respectively. According to drugs.com and medscape.com, the results show three clinically significant combinations:aspirin-enalapril (37.4%), clopidogrel-esomeprazole (31.3%), and aspirin-captopril (20%). Of all discovered drug interactions, 28.1% are estimated as major and 38.8% as moderate (monitor closely). The results show that aspirin is considered the first-line drug, and the aspirin-clopidogrel combination is more common than aspirin-ticagrelor in the treatment of acute myocardial infarction patients. Aspirin-enalapril, clopidogrelesomeprazole, and aspirin-captopril are clinically significant interactions avoided in indicating.